CME PROGRAMS +++++++

CME PROGRAMS Skeletal Involvement in Lysosomal Disorders https://checkrare.com/learning/p-skeletal-involvement-in-lysosomal-disorders/ Ozlem Goker-Alpan, MD, Founder and President, Lysosomal & Rare Disorders Research & Treatment Center (LDRTC) and Ravi Kamath, MD, PhD, of Fairfax Radiological Consultants & Inova Health System and University of Virginia School of Medicine Fairfax, Virginia, USA discuss best practices to identify and treat bone problems associated with lysosomal disorders. CREDITS: 1.0 CME | DURATION: 1.0 hours EXPIRES: 6/30/2026 | FEE: $0 Fabry Disease Research Highlights https://checkrare.com/learning/p-fabry-disease-research-highlights-2025/ Eric Wallace, MD, provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease. CREDITS: 0.5 CME | DURATION: 0.5 hours EXPIRES: 5/15/2026 | FEE: $0 Transforming Clinical Outcomes with Early Treatment of Lysosomal Disorders https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/ Ozlem Goker-Alpan MD, David F. Kronn, MD, Uma Ramaswami FRCPCH, MD, Liz Jalazo, MD, and Lindsay Torrice MSN, CPNP-PC, examine the evidence available to address how to monitor, and possibly treat, children with lysosomal diseases that were diagnosed by newborn screening or soon after birth. CREDITS: 1.00 CME | DURATION: 1 hour EXPIRES: 4/03/2026 | FEE: $0 Consider Rare: Suspecting and Diagnosing Hereditary Angioedema https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/ Jonathan A Bernstein, MD, describes the early symptoms of HAE and its clinical relevance, and discusses best practices to diagnose HAE more efficiently to reduce diagnostic delays. CREDITS: 0.50 CME | DURATION: 30 minutes EXPIRES: 3/15/2026 | FEE: $0 Hematologic Malignancies and Clinical Trial Participation: A Shared Decision-Making Approach https://checkrare.com/learning/p-hematologic-malignancies-and-clinical-trial-participation-a-shared-decision-making-approach/ John Kuruvilla, MD, explores best practices for discussing possible clinical trial participation with patients who have hematologic malignancies. CREDITS: 0.50 CME | DURATION: 30 minutes EXPIRES: 11/30/2025 | FEE: $0 Complement-Mediated Kidney Disorders: A Case Series https://checkrare.com/learning/p-complement-mediated-kidney-disorders-a-case-series/ Howard Trachtman, MD, FASN, and Carla M. Nester, MD, MSA, FASN, utilizes three unique case studies to address clinical questions which explore the complexities involved in diagnosing, treating, and managing patients with various complement-mediated kidney disorders, such as C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). CREDITS: 0.75 CME | DURATION: 45 minutes EXPIRES: 11/15/2025 | FEE: $0 Cushing’s Syndrome Treatment Research Highlights: ENDO 2024 https://checkrare.com/learning/p-cushings-syndrome-treatment-research-highlights-endo-2024/ Maria Fleseriu, MD, FACE, Professor of Medicine and Neurological Surgery, Director of the Pituitary Center at Oregon Health & Science University, provides an overview of the latest clinical research presented at ENDO 2024 involving Cushing’s syndrome. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 9/29/2025 | FEE: $0 FcRn and Myasthenia Gravis https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis/ Richard J. Nowak, MD, MS, explains the role of neonatal fragment crystallizable receptor (FcRn) in myasthenia gravis (MG) and how treatments that target FcRn are being used to manage patients with MG. CREDITS: 0.5 CME | DURATION: 30 minutes EXPIRES: 11/06/2025 | FEE: $0